CA2543072A1 — Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
Assigned to Valneva Austria GmbH · Expires 2005-06-02 · 21y expired
What this patent protects
The present invention provides novel adjuvant systems that reduce the risk of toxic side effects associated with the use of known adjuvants while providing powerful stimulation of immune responses against target antigens. These novel adjuvant systems are based on the honey bee ve…
USPTO Abstract
The present invention provides novel adjuvant systems that reduce the risk of toxic side effects associated with the use of known adjuvants while providing powerful stimulation of immune responses against target antigens. These novel adjuvant systems are based on the honey bee venom melittin or specific cationic peptides derived from melittin and ae capable of eliciting strong immune responses against target antigens. To further enhance their immunogenicity they can be optionally combined with synthetic oligonucleotides (ODNs) lacking any immunostimulatory sequences such as CpG motifs.
Drugs covered by this patent
- Parsabiv (ETELCALCETIDE) · Kai Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.